-
81.发明授权Production and use of novel peptide-based agents for use with bi-specific antibodies 有权用于双特异性抗体的新型基于肽的试剂的生产和使用公开(公告)号：US07943343B2
公开(公告)日：2011-05-17
申请号：US12582009
申请日：2009-10-20
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
摘要翻译： 本发明涉及一种双特异性抗体或抗体片段，该双特异性抗体或抗体片段具有至少一个对目标组织有反应性的臂和至少一种其它可靶向缀合物反应的其他臂。 可靶向缀合物包含已制备抗体的半抗原。 在优选的实施方案中，半抗原是组胺 - 琥珀酰甘氨酸（HSG）。 在更优选的实施方案中，所述至少一个臂包含HSG结合679抗体的CDR序列。 可靶向缀合物连接至一种或多种治疗和/或诊断剂。 本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法和包含它们的试剂盒。
-
公开(公告)号：US07931903B2
公开(公告)日：2011-04-26
申请号：US12794823
申请日：2010-06-07
IPC分类号： A61K39/395
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
-
公开(公告)号：US07919087B2
公开(公告)日：2011-04-05
申请号：US11754902
申请日：2007-05-29
IPC分类号： A61K39/395 , A61K39/40
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
摘要翻译： 本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。
-
公开(公告)号：US20110052489A1
公开(公告)日：2011-03-03
申请号：US12907262
申请日：2010-10-19
IPC分类号： A61K51/10 , A61K39/395 , A61K49/00 , A61K38/21 , A61K38/19 , A61K49/22 , A61P35/02 , A61P37/06
CPC分类号： C07K16/2803 , A61K38/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1069 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/2809 , C07K16/283 , C07K16/2833 , C07K16/2887 , C07K16/30 , C07K16/3061 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/92
摘要： The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.
摘要翻译： 本发明提供了结合人B细胞标记的人源化，嵌合和人抗CD19抗体，抗-CD19抗体融合蛋白及其片段。 此类抗体，融合蛋白及其片段可用于治疗和诊断各种B细胞病症，包括B细胞恶性肿瘤和自身免疫性疾病。 在更具体的实施方案中，人源化抗CD19抗体可以包含设计用于改善蛋白质稳定性，抗体结合和/或表达水平的一个或多个框架区氨基酸取代。 在特别优选的实施方案中，所述取代包括hA19 VH序列中的Ser91Phe取代。
-
公开(公告)号：US20100196267A1
公开(公告)日：2010-08-05
申请号：US12556718
申请日：2009-09-10
IPC分类号： A61K51/10 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/395 , A61P29/00 , A61P25/28 , A61P37/00
CPC分类号： C07K16/2833 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2887 , C07K16/4241 , C07K19/00 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92
摘要： Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.
摘要翻译： 提供特异性结合HLA-DR的人源化抗体。 抗体识别由鼠单克隆抗体L243识别的表位。 提供了制备此类抗体的方法，含有此类抗体的药物组合物，以及临床治疗和诊断以及用于此类抗体的研究相关用途。
-
86.发明申请Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies 审中-公开用于双特异性抗体的新型基于肽的试剂的生产和使用公开(公告)号：US20100158803A1
公开(公告)日：2010-06-24
申请号：US12683538
申请日：2010-01-07
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
摘要翻译： 本发明涉及一种双特异性抗体或抗体片段，该双特异性抗体或抗体片段具有至少一个对目标组织有反应性的臂和至少一种其它可靶向缀合物反应的其他臂。 可靶向缀合物包含已制备抗体的半抗原。 在优选的实施方案中，半抗原是组胺 - 琥珀酰甘氨酸（HSG）。 在更优选的实施方案中，所述至少一个臂包含HSG结合679抗体的CDR序列。 可靶向缀合物连接至一种或多种治疗和/或诊断剂。 本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法和包含它们的试剂盒。
-
公开(公告)号：US20100074840A1
公开(公告)日：2010-03-25
申请号：US12564335
申请日：2009-09-22
IPC分类号： A61K39/395 , A61P35/00 , A61K51/00
CPC分类号： A61K47/48569 , A61K31/704 , A61K31/7056 , A61K31/706 , A61K45/06 , A61K47/6809 , A61K47/6849 , A61K47/6889 , C07H17/00 , C07H17/02 , C07K16/18 , C07K16/2896
摘要： The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety.
摘要翻译： 本发明涉及具有靶向各种抗原能力的治疗性缀合物。 缀合物含有靶向抗体或其抗原结合片段和蒽环类化疗药物。 靶向抗体和化学治疗药物通过包含酰肼部分的接头连接。
-
88.发明授权Production and use of novel peptide-based agents for use with bi-specific antibodies 有权用于双特异性抗体的新型基于肽的试剂的生产和使用公开(公告)号：US07666415B2
公开(公告)日：2010-02-23
申请号：US12481233
申请日：2009-06-09
IPC分类号： A61K49/14 , A61K39/395
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
摘要翻译： 本发明涉及一种双特异性抗体或抗体片段，该双特异性抗体或抗体片段具有至少一个对目标组织有反应性的臂和至少一种其它可靶向缀合物反应的其他臂。 可靶向缀合物包含已制备抗体的半抗原。 在优选的实施方案中，半抗原是组胺 - 琥珀酰甘氨酸（HSG）。 在更优选的实施方案中，所述至少一个臂包含HSG结合679抗体的CDR序列。 可靶向缀合物连接至一种或多种治疗和/或诊断剂。 本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法和包含它们的试剂盒。
-
89.发明申请公开(公告)号：US20090274649A1
公开(公告)日：2009-11-05
申请号：US12352632
申请日：2009-01-13
CPC分类号： B82Y5/00 , A61K47/6897 , A61K51/109 , A61K2039/505 , C07K16/3007 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/524 , C07K2317/53 , C07K2317/622 , C07K2317/94
摘要： A mutant bispecific antibody that includes (a) a human hinge constant region from IgG having one or more amino acid mutations in the CH2 domain, (b) two scFvs; and (c) two Fvs has been constructed. This type of antibody displays enhanced clearance, which has been found to be particularly useful in the context of pre-targeting methods.
摘要翻译： 一种突变双特异性抗体，其包括（a）来自IgG的人铰链恒定区，其在CH2结构域中具有一个或多个氨基酸突变，（b）两个scFv; 和（c）两个Fvs已经建成。 这种类型的抗体显示增强的清除率，已被发现在预先靶向方法的背景下特别有用。
-
公开(公告)号：US07612180B2
公开(公告)日：2009-11-03
申请号：US11368296
申请日：2006-03-03
IPC分类号： C12P21/08
CPC分类号： C07K16/2833 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2887 , C07K16/4241 , C07K19/00 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92
摘要： Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapuetic and diagnostic, as well as research-related uses for such antibodies, are provided.
摘要翻译： 提供特异性结合HLA-DR的人源化抗体。 抗体识别由鼠单克隆抗体L243识别的表位。 提供了制备此类抗体的方法，含有此类抗体的药物组合物，以及临床治疗和诊断以及用于此类抗体的研究相关用途。
-
-
-
-
-
-
-
-
-
搜索结果
94 条记录 (耗时 0.068 秒)
